Fig. 2From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancerA forest plot for a progression-free survival hazard ratios and b overall survival hazard ratios comparing Del-19 group with L858R group for subgroups stratified by the indicated factorsBack to article page